Havemeyer Place LP Takes Position in Glaukos Corporation $GKOS

Havemeyer Place LP bought a new stake in Glaukos Corporation (NYSE:GKOS) during the fourth quarter, Holdings Channel reports. The institutional investor bought 13,557 shares of the medical instruments supplier’s stock, valued at approximately $1,531,000.

Other large investors also recently modified their holdings of the company. AustralianSuper Pty Ltd lifted its holdings in shares of Glaukos by 10.8% in the third quarter. AustralianSuper Pty Ltd now owns 449,846 shares of the medical instruments supplier’s stock valued at $36,685,000 after purchasing an additional 43,750 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Glaukos by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 670,083 shares of the medical instruments supplier’s stock valued at $54,645,000 after purchasing an additional 27,646 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Glaukos by 460.8% in the fourth quarter. SG Americas Securities LLC now owns 60,232 shares of the medical instruments supplier’s stock valued at $6,801,000 after purchasing an additional 49,492 shares in the last quarter. TD Asset Management Inc bought a new position in shares of Glaukos in the third quarter valued at approximately $1,157,000. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Glaukos by 32.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 355,279 shares of the medical instruments supplier’s stock valued at $39,336,000 after purchasing an additional 87,781 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the transaction, the director owned 35,528 shares in the company, valued at approximately $5,000,921.28. This represents a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 19,573 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.54, for a total value of $2,809,508.42. Following the completion of the transaction, the chief operating officer owned 73,419 shares in the company, valued at approximately $10,538,563.26. The trade was a 21.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,930 shares of company stock worth $6,321,363 over the last 90 days. 5.90% of the stock is currently owned by corporate insiders.

Glaukos Price Performance

Shares of NYSE GKOS opened at $124.79 on Friday. Glaukos Corporation has a twelve month low of $73.16 and a twelve month high of $148.11. The stock’s 50 day moving average price is $122.29 and its 200-day moving average price is $115.12. The company has a market capitalization of $7.33 billion, a PE ratio of -38.05 and a beta of 0.82. The company has a quick ratio of 4.73, a current ratio of 5.43 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million for the quarter, compared to the consensus estimate of $137.00 million. During the same quarter in the previous year, the business earned ($0.22) EPS. The company’s revenue was up 41.2% compared to the same quarter last year. On average, equities analysts anticipate that Glaukos Corporation will post -0.57 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on GKOS. Weiss Ratings restated a “sell (d-)” rating on shares of Glaukos in a report on Tuesday, April 21st. JPMorgan Chase & Co. raised their target price on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Stifel Nicolaus set a $170.00 target price on Glaukos in a report on Thursday, April 30th. Citigroup boosted their target price on Glaukos from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Finally, Wells Fargo & Company boosted their target price on Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $146.17.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.